I/UCRC: Technology Innovation for Novel Cost-reducing and Quality-enhancing Musculoskeletal Therapies

I/UCRC破坏性肌肉骨骼创新计划汇集医疗器械设计方面的专业知识；材料、纳米技术和医学成像的新进展；计算机建模;肌肉骨骼护理方面的临床专业知识；医疗器械创新的商业敏锐度；以及对包括临床结果和成本数据在内的大型国家数据库的分析。通过这样做，CDMI有潜力通过将这些学术技能与医疗技术（MedTech）行业的迫切需求联系起来，促进知识的发展。CDMI计划开展涉及多个学科的研究，包括材料科学、生物医学工程、纳米技术、生物传感器、植入物设计、信息技术和先进成像，这些都有可能降低成本和改善结果。医疗技术产业在美国经济中扮演着重要角色。然而，美国上市前的监管程序，加上覆盖范围和报销的不确定性，对创新造成了重大阻碍，并使美国？美国的领导地位岌岌可危。如果没有对一项新的医疗技术会得到支付的信心，工业界就无法证明将该技术推向市场所需的投资是合理的。因此，社会迫切需要从花费在医疗技术上的资金中创造更多价值，从而在不牺牲创新效益的情况下管理医疗成本的增长。美国若要保持其在医疗技术领域的领导地位，就需要将医疗保健资金用于促进可持续创新的方式。CDMI的合作研究努力在一定程度上力求提供一个实现这些目标的框架。

The I/UCRC for Disruptive Musculoskeletal Innovations intends to bring together expertise in medical device design; new advancements in materials, nano-technology, and medical imaging; computer modeling; clinical expertise in musculoskeletal care; business acumen for medical device innovation; and analysis of large national databases that include both clinical outcomes and cost data. By doing so, CDMI has the potential to advance knowledge by bridging these academic skills to pressing needs of the medical technology (MedTech) industry. CDMI plans to conduct research encompassing multiple disciplines, including material science, biomedical engineering, nanotechnology, biosensors, implant design, information technology, and advanced imaging that have the potential to reduce costs and improve outcomes.The med-tech industry has an important role in the US economy. However, US pre-market regulatory processes, combined with coverage and reimbursement uncertainties, create significant deterrents to innovation, and places America?s leadership position in jeopardy. Without confidence that a new medical technology will be paid for, industry cannot justify the investment required to bring that technology to market. As a result, there is a pressing societal need to create more value from the money spent on medical technology, and thereby manage healthcare cost increases without sacrificing the benefits of innovation.For the US to maintain its leadership in medical technologies, healthcare dollars need to be channeled in ways to foster innovation that is sustainable. The cooperative research efforts of the CDMI seek to provide, in part, a framework to achieve these ends.